Supernus Operating Income vs Cost of Revenue Analysis

SUPN Stock

USD 30.26 0.31 1.04%

Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Operating Income and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Operating Income vs Cost Of Revenue

Operating Income vs Cost of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Operating Income account and Cost of Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Supernus Pharmaceuticals' Operating Income and Cost of Revenue is -0.05. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Operating Income and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Supernus Pharmaceuticals are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Operating Income i.e., Supernus Pharmaceuticals' Operating Income and Cost of Revenue go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Supernus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Supernus Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Supernus Pharmaceuticals income statement and represents the costs associated with goods and services Supernus Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 25th of April 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.

	2021	2022	2023	2024 (projected)
Interest Expense	23.4M	7.1M	2.4M	2.3M
Depreciation And Amortization	34.0M	82.6M	84.9M	89.1M

Interest Expense Depreciation And Amortization

Supernus Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock
Common Stock Shares Outstanding		0.64	0.55	0.36	0.61	0.63	0.42	0.4	0.47	0.35	0.46	0.61	-0.14	0.64	0.7	0.93	0.6	0.45	0.58	0.64	0.91	0.63	0.53	0.69	0.45	0.94
Total Assets	0.64		0.68	0.63	0.81	0.98	0.77	0.7	0.95	0.63	0.64	0.99	-0.38	0.9	0.98	0.62	0.81	0.76	0.93	0.89	0.84	0.94	0.91	0.94	0.88	0.61
Short Long Term Debt Total	0.55	0.68		-0.01	0.67	0.55	0.28	0.81	0.5	0.69	0.73	0.62	-0.56	0.85	0.64	0.46	0.67	0.73	0.47	0.71	0.66	0.83	0.6	0.82	0.42	0.49
Other Current Liab	0.36	0.63	-0.01		0.45	0.74	0.62	0.14	0.74	-0.01	0.05	0.65	0.05	0.38	0.69	0.38	0.5	0.2	0.73	0.39	0.46	0.38	0.44	0.45	0.66	0.34
Total Current Liabilities	0.61	0.81	0.67	0.45		0.77	0.41	0.78	0.78	0.72	0.31	0.78	-0.42	0.82	0.82	0.54	0.94	0.41	0.83	0.73	0.7	0.83	0.65	0.87	0.78	0.54
Total Stockholder Equity	0.63	0.98	0.55	0.74	0.77		0.84	0.57	0.97	0.51	0.53	0.99	-0.27	0.82	0.98	0.63	0.77	0.66	0.94	0.83	0.81	0.85	0.9	0.87	0.89	0.61
Property Plant And Equipment Net	0.42	0.77	0.28	0.62	0.41	0.84		0.27	0.82	0.18	0.48	0.8	0.08	0.58	0.75	0.46	0.47	0.57	0.68	0.6	0.61	0.59	0.89	0.61	0.64	0.43
Net Debt	0.4	0.7	0.81	0.14	0.78	0.57	0.27		0.58	0.73	0.51	0.66	-0.6	0.85	0.62	0.29	0.83	0.65	0.58	0.66	0.54	0.85	0.61	0.81	0.53	0.31
Retained Earnings	0.47	0.95	0.5	0.74	0.78	0.97	0.82	0.58		0.52	0.44	0.96	-0.28	0.78	0.94	0.46	0.75	0.6	0.94	0.79	0.69	0.82	0.88	0.83	0.92	0.43
Accounts Payable	0.35	0.63	0.69	-0.01	0.72	0.51	0.18	0.73	0.52		0.54	0.62	-0.71	0.66	0.57	0.3	0.57	0.59	0.62	0.78	0.5	0.78	0.57	0.7	0.69	0.33
Cash	0.46	0.64	0.73	0.05	0.31	0.53	0.48	0.51	0.44	0.54		0.6	-0.27	0.75	0.58	0.47	0.36	0.91	0.35	0.68	0.64	0.74	0.64	0.7	0.35	0.51
Non Current Assets Total	0.61	0.99	0.62	0.65	0.78	0.99	0.8	0.66	0.96	0.62	0.6		-0.38	0.86	0.98	0.6	0.77	0.75	0.94	0.89	0.82	0.91	0.92	0.91	0.9	0.59
Non Currrent Assets Other	-0.14	-0.38	-0.56	0.05	-0.42	-0.27	0.08	-0.6	-0.28	-0.71	-0.27	-0.38		-0.38	-0.31	-0.12	-0.34	-0.46	-0.4	-0.6	-0.29	-0.52	-0.29	-0.42	-0.45	-0.14
Cash And Short Term Investments	0.64	0.9	0.85	0.38	0.82	0.82	0.58	0.85	0.78	0.66	0.75	0.86	-0.38		0.87	0.61	0.88	0.79	0.72	0.82	0.83	0.96	0.8	0.98	0.66	0.62
Net Receivables	0.7	0.98	0.64	0.69	0.82	0.98	0.75	0.62	0.94	0.57	0.58	0.98	-0.31	0.87		0.66	0.79	0.68	0.93	0.86	0.85	0.89	0.85	0.92	0.88	0.66
Common Stock Total Equity	0.93	0.62	0.46	0.38	0.54	0.63	0.46	0.29	0.46	0.3	0.47	0.6	-0.12	0.61	0.66		0.57	0.44	0.54	0.66	0.93	0.58	0.53	0.66	0.43	0.99
Short Term Investments	0.6	0.81	0.67	0.5	0.94	0.77	0.47	0.83	0.75	0.57	0.36	0.77	-0.34	0.88	0.79	0.57		0.46	0.76	0.67	0.73	0.83	0.66	0.89	0.67	0.56
Non Current Liabilities Total	0.45	0.76	0.73	0.2	0.41	0.66	0.57	0.65	0.6	0.59	0.91	0.75	-0.46	0.79	0.68	0.44	0.46		0.53	0.82	0.69	0.85	0.76	0.78	0.52	0.45
Inventory	0.58	0.93	0.47	0.73	0.83	0.94	0.68	0.58	0.94	0.62	0.35	0.94	-0.4	0.72	0.93	0.54	0.76	0.53		0.82	0.73	0.81	0.8	0.81	0.97	0.53
Other Current Assets	0.64	0.89	0.71	0.39	0.73	0.83	0.6	0.66	0.79	0.78	0.68	0.89	-0.6	0.82	0.86	0.66	0.67	0.82	0.82		0.85	0.93	0.83	0.89	0.83	0.64
Other Stockholder Equity	0.91	0.84	0.66	0.46	0.7	0.81	0.61	0.54	0.69	0.5	0.64	0.82	-0.29	0.83	0.85	0.93	0.73	0.69	0.73	0.85		0.83	0.75	0.87	0.64	0.92
Total Liab	0.63	0.94	0.83	0.38	0.83	0.85	0.59	0.85	0.82	0.78	0.74	0.91	-0.52	0.96	0.89	0.58	0.83	0.85	0.81	0.93	0.83		0.84	0.98	0.77	0.59
Property Plant And Equipment Gross	0.53	0.91	0.6	0.44	0.65	0.9	0.89	0.61	0.88	0.57	0.64	0.92	-0.29	0.8	0.85	0.53	0.66	0.76	0.8	0.83	0.75	0.84		0.82	0.77	0.53
Total Current Assets	0.69	0.94	0.82	0.45	0.87	0.87	0.61	0.81	0.83	0.7	0.7	0.91	-0.42	0.98	0.92	0.66	0.89	0.78	0.81	0.89	0.87	0.98	0.82		0.75	0.66
Intangible Assets	0.45	0.88	0.42	0.66	0.78	0.89	0.64	0.53	0.92	0.69	0.35	0.9	-0.45	0.66	0.88	0.43	0.67	0.52	0.97	0.83	0.64	0.77	0.77	0.75		0.42
Common Stock	0.94	0.61	0.49	0.34	0.54	0.61	0.43	0.31	0.43	0.33	0.51	0.59	-0.14	0.62	0.66	0.99	0.56	0.45	0.53	0.64	0.92	0.59	0.53	0.66	0.42

Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	53.8M	53.7M	54.4M	61.7M	55.5M	42.6M
Total Assets	1.2B	1.5B	1.7B	1.7B	1.4B	1.5B
Short Long Term Debt Total	375.6M	390.3M	420.6M	438.0M	41.5M	39.5M
Other Current Liab	3.2M	40.0M	65.0M	139.8M	279.9M	293.9M
Total Current Liabilities	160.6M	245.1M	315.4M	688.0M	290.2M	154.7M
Total Stockholder Equity	595.4M	744.9M	815.9M	886.2M	921.5M	967.6M
Property Plant And Equipment Net	38.3M	37.8M	17.0M	15.2M	42.5M	44.7M
Net Debt	194.2M	101.7M	217.1M	344.8M	(33.5M)	(31.9M)
Retained Earnings	199.5M	326.5M	379.9M	481.2M	482.6M	506.7M
Accounts Payable	10.1M	78.9M	117.7M	96.3M	2.0M	1.9M
Cash	181.4M	288.6M	203.4M	93.1M	75.1M	116.1M
Non Current Assets Total	687.6M	873.7M	1.1B	968.4M	915.9M	961.7M
Non Currrent Assets Other	615K	8.0M	(36.1M)	(10.0M)	8.5M	8.9M
Cash And Short Term Investments	347.1M	422.5M	339.7M	461.3M	254.9M	201.2M
Net Receivables	87.3M	140.9M	148.9M	165.5M	144.2M	151.4M
Common Stock Total Equity	51K	52K	53K	54K	62.1K	40.8K
Short Term Investments	165.7M	133.9M	136.2M	368.2M	179.8M	98.1M
Liabilities And Stockholders Equity	1.2B	1.5B	1.7B	1.7B	1.4B	1.5B
Non Current Liabilities Total	404.3M	514.1M	557.9M	128.3M	197.3M	179.2M
Inventory	26.6M	48.3M	86.0M	91.5M	77.4M	81.3M
Other Current Assets	11.6M	18.7M	27.0M	15.8M	16.7M	8.5M
Other Stockholder Equity	388.4M	409.3M	434.3M	408.1M	439.5M	279.8M
Total Liab	564.9M	759.2M	873.3M	816.3M	487.5M	333.9M
Property Plant And Equipment Gross	38.3M	37.8M	33.4M	28.2M	28.9M	30.4M
Total Current Assets	472.6M	630.4M	601.6M	734.2M	493.1M	305.3M
Accumulated Other Comprehensive Income	7.4M	9.0M	1.5M	(3.2M)	(593K)	(563.4K)
Intangible Assets	24.8M	442.3M	784.7M	702.5M	599.9M	629.9M
Common Stock	51K	52K	53K	54K	55K	42.0K
Other Liab	28.7M	123.8M	137.4M	92.3M	106.2M	111.5M
Other Assets	32.7M	259.7M	13.9M	10.9M	12.5M	11.9M
Long Term Debt	329.5M	345.2M	361.8M	379.3M	436.1M	457.9M
Property Plant Equipment	17.1M	37.8M	52.3M	44.1M	50.7M	53.2M
Net Tangible Assets	570.6M	302.6M	(86.4M)	66.7M	76.7M	72.9M
Good Will	24.8M	77.9M	117.5M	117.0M	134.6M	141.3M
Retained Earnings Total Equity	199.5M	326.5M	379.9M	481.2M	553.4M	581.1M
Capital Surpluse	388.4M	409.3M	434.3M	408.1M	469.3M	352.1M

Currently Active Assets on Macroaxis

S	SentinelOne
GM	General Motors
V	Visa Class A
C	Citigroup
C	Citigroup

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	CEOs Directory Screen CEOs from public companies around the world
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities

Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.96)

Earnings Share

0.02

Revenue Per Share

11.14

Quarterly Revenue Growth

(0.02)

Return On Assets

0.0056

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Operating Income vs Cost of Revenue Analysis

Operating Income vs Cost Of Revenue

Operating Income vs Cost of Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Cost Of Revenue

Supernus Pharmaceuticals fundamental ratios Correlations

Supernus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Supernus Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Supernus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Common Stock Total Equity
Total Stockholder Equity	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Stockholder Equity

Non Currrent Assets Other	- 0.71	Accounts Payable
Other Current Assets	- 0.6	Non Currrent Assets Other
Non Currrent Assets Other	- 0.6	Net Debt
Non Currrent Assets Other	- 0.56	Short Long Term Debt Total
Total Liab	- 0.52	Non Currrent Assets Other
Non Current Liabilities Total	- 0.46	Non Currrent Assets Other